Eligibility:

Ages Eligible for Study: 2 years of age or older
Genders Eligible for Study: Both

Inclusion Criteria:

• Informed Consent Form signed by the patient or patient's legal representative; also, if the patient is under the age of majority but capable of providing assent, signed assent from the patient
• Diagnosis of junctional or dystrophic EB.
• Patients who present with Hallopeau-Siemens subtype may be enrolled.
• At least one active, unroofed EB erosion on the limb or on the trunk.
• Lesion size 5 to 50 cm², inclusive.
• Stable lesion present for 14-60 days before enrollment.

Exclusion Criteria:

• Clinical evidence of local infection of the index (targeted) lesion.
• Use of any investigational drug within the 30 days before enrollment.
• Use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment.
• Clinically significant abnormalities on Screening laboratory tests, except for the following specific laboratory threshold result:
  - albumin <2.0 g/dL.
  - hemoglobin < 8 g/dL
• Use of systemic or topical steroidal therapy within the 30 days before enrollment. (except inhaled steroids)
• Use of systemic antibiotics within the 7 days before enrollment.
• Current or former malignancy.
• Arterial or venous disorder resulting in ulcerated wounds.
• Diabetes mellitus.
• Pregnancy or breastfeeding during the study. (A serum pregnancy test will be performed at Screening for female patients of childbearing potential.)